New oral anticoagulants and oculoplastic surgery.
The use of oral anticoagulants is increasing because of the rising prevalence of atrial fibrillation and other cardiovascular diseases that occur in an aging population. In the last decade, several new oral anticoagulants have emerged, comprising the direct thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban and rivaroxaban. Although these new anticoagulants may not affect clear corneal cataract surgery, their use will impact the management of patients having eyelid, orbital, and nasolacrimal procedures. The objective of this review is to provide a concise and practical approach to the perioperative management of patients who require an oculoplastic procedure and are receiving these new anticoagulants.
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont. Electronic address: edinglidstrab@gmail.com.
Edsel
E
Ing
Department of Medicine, McMaster University, Hamilton, Ont.
James
J
Douketis
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002387:Cataract Extraction; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011728:Pyridones / Q000008:administration & dosage; D000069552:Rivaroxaban; D013518:Surgery, Plastic; D013876:Thiophenes / Q000008:administration & dosage; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives
D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran